Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

Published:2022-02 Issue:2 Volume:23 Page:259-269
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Safran Howard P,Winter Kathryn,Ilson David H,Wigle Dennis,DiPetrillo Thomas,Haddock Michael G,Hong Theodore S,Leichman Lawrence P,Rajdev Lakshmi,Resnick Murray,Kachnic Lisa A,Seaward Samantha,Mamon Harvey,Diaz Pardo Dayssy Alexandra,Anderson Carryn M,Shen Xinglei,Sharma Anand K,Katz Alan W,Salo Jonathan,Leonard Kara L,Moughan Jennifer,Crane Christopher H

Funder

Genentech Inc

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial;Shapiro;Lancet Oncol,2015

2. Untangling the ErbB signalling network;Yarden;Nat Rev Mol Cell Biol,2001

3. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer;Vogel;J Clin Oncol,2002

4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

5. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study;Translational Oncology;2024-11

2. A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions;International Journal of Cancer;2024-09-14

3. Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases;Drug Resistance Updates;2024-09

4. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

5. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction;JAMA Network Open;2024-08-02